Viveve Medical's (VIVE) Viveve System Receives FDA 510(k) Clearance

October 6, 2016 4:02 PM EDT
Get Alerts VIVE Hot Sheet
Trade VIVE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Viveve Medical, Inc. (Nasdaq: VIVE) announced that the Viveve System has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA). In the United States, the Viveve System is now indicated for use in general surgical procedures for electrocoagulation and hemostasis.

"FDA 510(k) clearance for the Viveve System represents a major milestone in our efforts to bring this safe and effective technology to patients in the United States who can benefit from it," said Patricia Scheller, chief executive officer of Viveve. "We are grateful to all of the clinicians and researchers who have supported the development of the Viveve System over the past several years, and to all of the members of the Viveve team who played a vital role in helping us achieve this goal."

"This clearance represents the first step in our U.S. regulatory strategy," Scheller added. "In September 2016, we announced that the company filed an Investigational Device Exemption (IDE) to the FDA, for authorization to begin the VIveve Treatment of the Vaginal Introitus to EValuate Efficacy (VIVEVE II) study."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Add Your Comment